FGP
APLS

Freestone Grove Partners’s Apellis Pharmaceuticals APLS Stock Holding History

Freestone Grove Partners’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,537
Closed -$315K – 979
2025
Q4 		$315K Buy
+12,537
New +$294K ﹤0.01% 651

Other funds holding APLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Freestone Grove Partners's APLS Position: Q1 2026 in Review

Freestone Grove Partners sold out of Apellis Pharmaceuticals (APLS) in Q1 2026, closing a stake of 12,537 shares — an estimated $315K sold.

Freestone Grove Partners first reported a position in APLS in Q4 2025 and held it in 1 quarter. The position peaked at $315K in Q4 2025. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Freestone Grove Partners reported no remaining Apellis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Freestone Grove Partners sold 12,537 Apellis Pharmaceuticals shares in Q1 2026, an estimated $315K.
  • Freestone Grove Partners first reported a position in Apellis Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Freestone Grove Partners's Apellis Pharmaceuticals position peaked at $315K in Q4 2025.
  • 323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Freestone Grove Partners's 13F filing for Q1 2026, filed 15 May 2026.